The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human CFD
World Psychiatry 13 , 411 (2014)
The position statements of the American Academy of Clinical Toxicology (AACT) suggests the following when applied to large VPA overdose (ref 12 to 14) SDAC Should not be administered as a routine intervention It can be considered up to an hour post ingestion (4 hours in slow or enteric release preparations) in those who have ingested potentially toxic dose, and who have an intact, protected airway Usual dose is 1gm/kg MDAC Reported to be used in multiple cases of VPA overdose, but AACT position statement states that there is no evidence that MDAC increases the elimination of VPA, and should only be considered in specific overdoses (carbemazepine, dapsone, phenobarbitone, quinine, or theophylline) it may aid decontamination (rather than enhanced elimination) given the slow absorption of valproate WBI consider in sustained release or enteric-coated ingestions that are potentially toxic or life threatening in patients presenting greater than two hours
DOI: 10.1001/jamapsychiatry.2020.0246 Rickli A et al (2015): Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones
An increased risk of RA may be associated with dysfunction in the antioxidant system of fibroblast-like synovial cells (FLS), and various strategies to inhibit FLS proliferation and restore synovial homeostasis hold promise as potential treatment directions [158]
